Carballido J M, Aversa G, Schols D, Punnonen J, de Vries J E
Human Immunology Department, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304-1104, USA.
Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):304-7. doi: 10.1159/000237009.
In the present study, it is shown that a human interleukin (IL)-4 mutant protein (IL-4.Y124D) acts as a potent IL-4 and IL-13 receptor antagonist. Human (h) IL-4.Y124D efficiently inhibits both IL-4- and IL-13-induced IgE production in vitro. In addition, hIL-4.Y124D strongly inhibits ongoing human IgE synthesis in SCID-hu mice. These inhibitory effects are specific, since human IgG levels were not significantly affected. These results confirm the notion that the IL-4 and IL-13 receptor share a common component, which is required for signal transduction. In addition, they show that relatively large antagonistic polypeptides, such as hIL-4.Y124D have potential clinical utility in reducing IgE-mediated allergic diseases.
在本研究中，已表明一种人白细胞介素（IL）-4突变蛋白（IL-4.Y124D）可作为一种有效的IL-4和IL-13受体拮抗剂。人（h）IL-4.Y124D在体外能有效抑制IL-4和IL-13诱导的IgE产生。此外，hIL-4.Y124D强烈抑制SCID-hu小鼠中正在进行的人IgE合成。这些抑制作用具有特异性，因为人IgG水平未受到显著影响。这些结果证实了IL-4和IL-13受体共享一个信号转导所需的共同组分这一观点。此外，它们表明相对较大的拮抗多肽，如hIL-4.Y124D在减轻IgE介导的过敏性疾病方面具有潜在的临床应用价值。
